Vitalli Bio

Aditum Bio is a biotechnology investment company co-founded in 2019 by Joe Jimenez, former CEO of Novartis, and Dr. Mark Fishman, former President of the Novartis Institutes for BioMedical Research (NIBR), who is currently also a professor at Harvard Medical School. During Dr. Fishman's tenure, NIBR discovered and successfully conducted clinical trials for 120 new drugs across more than 90 indications. Vitalli Bio is the ninth company established by Aditum Bio, whose unique investment and operational model allows the company to quickly assemble, plan, and execute to advance new drug candidates into clinical trials and accelerate their delivery to patients in need. With the active involvement of Aditum Bio’s management team, which has extensive experience in the global pharmaceutical industry and clinical development, in the development of DWP213388, Vitalli Bio offers world-class development capabilities in major overseas countries such as the United States and Europe.